IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP

Study Overview
=================
Brief Summary
-----------------
To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP

Detailed Description
-----------------
Idiopathic thrombocytopenia or immune thrombocytopenia (ITP) is a hematological condition which is characterized by a low platelet count of less than 100 x 109L . Symptoms of ITP can vary but tend to be symptoms of thrombocytopenia in general, such as petechiae, purpura, mucosal bleeding and in the most severe cases fatal intracranial hemorrhage(1,2) Interleukin (IL)-37, a novel anti-inflammatory cytokine previously known as interleukin-1 family member 7 before it was renamed, has a pivotal role in the suppression of immune responses (3,4). IL-37 is widely expressed in several types of cells, tissues and organs, including peripheral blood mononuclear cells (PBMCs) (5). The major role of IL-37 is to decrease excessive inflammation in innate and adaptive immune diseases, mainly by inhibiting the expression, production and function of pro-inflammatory cytokines, including IL-1α, IL-6, tumor necrosis factor (TNF) and macrophage inflammatory protein-2. The abundance of these cytokines has been reported to increase with the silencing of endogenous IL-37 in human blood cells (3,6).Aberrant expression of IL-37 has been observed in several inflammatory and autoimmune diseases However, the role of IL-37 in ITP has remained elusive. Immune thrombocytopenia pathogenesis is a complicated process. T cell immune abnormalities are involved in ITP pathogenesis. These abnormalities include platelet auto-antigen reactive cytotoxic T cells, abnormal numbers and functions of T regulatory cells, loss of Th1/Th2 balance, megakaryocyte maturation abnormalities and abnormal T cell anergy.

Official Title
-----------------
IL37,Tlymphocytes ,NK Cells in Pathogenesis of Immune Thrombocytopenia.

Conditions
-----------------
ITP

Intervention / Treatment
-----------------
* Drug: Corticosteriod for treated patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with ITP (moderate and sever) different age group. Exclusion Criteria: Patients with stroke and myocardial infarction,malignant tumors or pregnancy.

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ITP<br>Patient newly diagnosied with ITP | Drug: Corticosteriod for treated patients<br>* Drug given to some patients with autoimmune disease<br>|
| Treated<br>Patients with ITP recived treatment | Drug: Corticosteriod for treated patients<br>* Drug given to some patients with autoimmune disease<br>|
| Control<br>Healthy people | Drug: Corticosteriod for treated patients<br>* Drug given to some patients with autoimmune disease<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To decrease the immunity complications in ITP patients | Early detection of immunity complications in ITP patients | Baseline | 
| To decrease case fatality rate | Early detection of immunity complication will decrease mortality rate | Baseline |